XNCR Xencor Inc
Price (delayed)
$9.82
Market cap
$691.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.58
Enterprise value
$882.63M
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in
Highlights
Xencor's debt has decreased by 8% YoY and by 3.9% QoQ
XNCR's equity is down by 4.4% since the previous quarter but it is up by 2.4% year-on-year
The company's net income has shrunk by 75% YoY and by 9% QoQ
The EPS has shrunk by 63% YoY and by 4.1% QoQ
Key stats
What are the main financial stats of XNCR
Market
Valuations
Earnings
Shares outstanding
70.46M
Market cap
$691.94M
Enterprise value
$882.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
5.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.99
Revenue
$110.49M
Gross profit
$110.49M
Operating income
-$178.41M
Net income
-$232.62M
EBIT
-$194.36M
EBITDA
-$182.25M
Free cash flow
-$208.29M
Per share
Balance sheet
Liquidity
EPS
-$3.58
EPS diluted
-$3.58
Free cash flow per share
-$3.2
Book value per share
$9.68
Revenue per share
$1.7
TBVPS
$14.35
Total assets
$951.95M
Total liabilities
$277.92M
Debt
$231.95M
Equity
$677.61M
Working capital
$490.17M
Debt to equity
0.34
Current ratio
6.61
Quick ratio
6.39
Net debt/EBITDA
-1.05
Margins
Efficiency
Dividend
EBITDA margin
-164.9%
Gross margin
100%
Net margin
-210.5%
Operating margin
-161.5%
Return on assets
-25.2%
Return on equity
-36.7%
Return on invested capital
-18.8%
Return on capital employed
-22.5%
Return on sales
-175.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XNCR stock price
How has the Xencor stock price performed over time
Intraday
1.34%
1 week
-11.17%
1 month
-36.07%
1 year
-54.35%
YTD
-57.27%
QTD
-7.71%
Financial performance
How have Xencor's revenue and profit performed over time
Revenue
$110.49M
Gross profit
$110.49M
Operating income
-$178.41M
Net income
-$232.62M
Gross margin
100%
Net margin
-210.5%
Xencor's net margin has shrunk by 176% YoY and by 7% QoQ
XNCR's operating margin has dropped by 113% year-on-year but it is up by 9% since the previous quarter
The company's net income has shrunk by 75% YoY and by 9% QoQ
The gross profit has decreased by 37% YoY
Growth
What is Xencor's growth rate over time
Valuation
What is Xencor stock price valuation
P/E
N/A
P/B
1.01
P/S
5.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.99
The EPS has shrunk by 63% YoY and by 4.1% QoQ
XNCR's P/B is 63% below its 5-year quarterly average of 2.7 and 52% below its last 4 quarters average of 2.1
XNCR's equity is down by 4.4% since the previous quarter but it is up by 2.4% year-on-year
XNCR's P/S is 54% below its 5-year quarterly average of 12.4 and 45% below its last 4 quarters average of 10.3
XNCR's revenue is down by 37% year-on-year
Efficiency
How efficient is Xencor business performance
The ROS has shrunk by 171% YoY and by 16% QoQ
XNCR's ROE has plunged by 85% YoY and by 9% from the previous quarter
The ROA has plunged by 58% YoY and by 10% from the previous quarter
The ROIC has contracted by 34% YoY and by 18% from the previous quarter
Dividends
What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XNCR.
Financial health
How did Xencor financials performed over time
XNCR's quick ratio is down by 24% year-on-year
The company's current ratio fell by 23% YoY
Xencor's debt is 66% lower than its equity
The debt to equity has decreased by 11% YoY
Xencor's debt has decreased by 8% YoY and by 3.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.